Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

Inclusion Criteria: 1. Subject (and/or a subject's authorized legal representative) has provided written informed consent 2. Patient meets the following criteria: * Outpatient status * PANSS Total Score ≤ 80 at screening and if PANSS score at baseline is ≥ 20% change from screening, the patients cannot participate in the study. * A score of ≤ 3 on the following PANSS items: * Conceptual disorganization * Suspiciousness * Hallucinatory behavior * Unusual thought content 3. Subject is male or female between 18 to 60 years of age 4. Subject has a diagnosis of schizophrenia or schizoaffective disorder according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria Exclusion Criteria: 1. Hospitalized or required acute crisis intervention for symptom exacerbation in the 60 days prior to admission as determined by the Investigator 2. Subject has a history of suicide attempt in the last year, or in the opinion of the investigator is currently at imminent risk of suicide 3. Has a current or recent (within 12 months) DSM-V diagnosis of moderate or severe substance use disorder (except for tobacco use disorder) or has a positive urine drug screen for prohibited substances at screening. 4. Have impaired hepatic (ALT/AST \>1.5 times higher than the upper limit of normal) or renal function (eGFR\<50 mL/min) 5. Previously defined hypersensitivity to Risperidone 6. History of neuromalignant syndrome (NMS) 7. Electroconvulsive therapy within 6 months of admission 8. Requires current use of agents that are strong inhibitors and inducers of cytochrome P450 2D6